KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Equity (2016 - 2025)

Historic Return on Equity for Nektar Therapeutics (NKTR) over the last 15 years, with Q3 2025 value amounting to 3.73%.

  • Nektar Therapeutics' Return on Equity fell 11100.0% to 3.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.73%, marking a year-over-year decrease of 11100.0%. This contributed to the annual value of 1.24% for FY2024, which is 1300.0% down from last year.
  • As of Q3 2025, Nektar Therapeutics' Return on Equity stood at 3.73%, which was down 11100.0% from 22.05% recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Return on Equity ranged from a high of 22.05% in Q2 2025 and a low of 3.73% during Q3 2025
  • Over the past 5 years, Nektar Therapeutics' median Return on Equity value was 1.36% (recorded in 2024), while the average stood at 0.28%.
  • The largest annual percentage gain for Nektar Therapeutics' Return on Equity in the last 5 years was 237600bps (2025), contrasted with its biggest fall of -20900bps (2025).
  • Over the past 5 years, Nektar Therapeutics' Return on Equity (Quarter) stood at 0.71% in 2021, then tumbled by -36bps to 0.96% in 2022, then plummeted by -97bps to 1.9% in 2023, then decreased by -14bps to 2.17% in 2024, then plummeted by -72bps to 3.73% in 2025.
  • Its Return on Equity stands at 3.73% for Q3 2025, versus 22.05% for Q2 2025 and 3.45% for Q1 2025.